11x Series A Announcement – Landscape SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) — 11x, a pioneering AI startup transforming the modern workforce with autonomous digital workers, announced closing a $24 million Series A funding round today. The round was led by Benchmark, with participation from Quiet Capital, SV Angel, Abstract Ventures, Lux Capital, Operator Partners, […]

PARIS and LONDON and NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) — Akur8, the machine learning-powered insurance pricing and reserving platform, announced today that it has secured $120 million in series C funding, bringing its total raised investment to $180 million. This latest funding round was led by One Peak, a leading growth equity firm […]

AI-Media and Speechmatics Partnership BROOKLYN, N.Y., Sept. 13, 2024 (GLOBE NEWSWIRE) — AI-Media – the global leader in audiovisual encoding technology and AI-driven transcription and translation solutions, and Speechmatics – the market leader in speech recognition technology, today announce a strategic expansion of their multi-year partnership to deliver new and better AI-driven products to market. […]

AI-Media and Speechmatics Partnership BROOKLYN, N.Y., Sept. 13, 2024 (GLOBE NEWSWIRE) — AI-Media – the global leader in audiovisual encoding technology and AI-driven transcription and translation solutions, and Speechmatics – the market leader in speech recognition technology, today announce a strategic expansion of their multi-year partnership to deliver new and better AI-driven products to market. […]

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering […]

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering […]